Management and monitoring of severe preeclampsia

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 96, Issue 1, 2001, Pages 8-20

  Bolte, Antoinette C ^a   Van Geijn, Herman P ^a   Dekker, Gustaaf A ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Conservative management; Eclampsia; HELLP syndrome; Preeclampsia

Indexed keywords

ANTIHYPERTENSIVE AGENT; CORTICOSTEROID; DIAZEPAM; KETANSERIN; MAGNESIUM SALT; MAGNESIUM SULFATE; NIMODIPINE; PHENYTOIN; PLASMA SUBSTITUTE; PROSTACYCLIN;

BLOOD VESSEL PERMEABILITY; BLOOD VESSEL REACTIVITY; BRAIN VASOSPASM; COLLOID; CONVULSION; CRYSTALLOID; DECISION MAKING; DELIVERY; DIASTOLIC BLOOD PRESSURE; DISEASE MANAGEMENT; ECLAMPSIA; FEMALE; FETUS; FETUS MONITORING; HEADACHE; HEART OUTPUT; HELLP SYNDROME; HUMAN; HYPERTENSION; HYPOVOLEMIA; LUNG EDEMA; MATERNAL MORTALITY; MONITORING; PLACENTA CIRCULATION; PLASMA VOLUME; PLASMAPHERESIS; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOCYTE COUNT; VASODILATATION;

EID: 0035057987     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(00)00383-3     Document Type: Review

References (122)

1. The pharmacological management of hypertension in pregnancy
2. Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy
3. Drug management of hypertensive disorders of pregnancy
4. Drug therapy: treatment of hypertension in pregnant women
5. Hypertensive drugs in pregnancy. Antihypertension therapy in pregnancy, preeclampsia, and eclampsia
6. Maternal central hemodynamics in hypertensive disorders of pregnancy
7. The renin-angiotensin-aldosterone system in preeclampsia. A review
8. Central hemodynamic observations in untreated preeclamptic patients
9. Plasma volume expansion in pregnancy hypertension
10. Antihypertensive effect of plasma volume expansion in pregnancy-associated hypertension
11. Fall in blood pressure in response to volume expansion in pregnancy-associated hypertension (pre-eclampsia): why does it occur?
12. Haemodynamic changes in gestational proteinuric hypertension: the effects of rapid volume expansion and vasodilator therapy
13. Cardiovascular alterations in severe pregnancy-induced hypertension: effects of intravenous nitroglycerin coupled with blood volume expansion
14. Quantitative hemodynamic effects of acute volume expansion in severe preeclampsia
15. Reappearance of end-diastolic velocities in the umbilical artery following maternal volume expansion: a preliminary study
16. Plasma volume expansion in the treatment of pre-eclampsia
17. Ketanserin versus dihydralazine in the management of severe early-onset preeclampsia: maternal outcome
18. Hypertensive disease in pregnancy
19. Maternal and perinatal outcome of temporizing management in 254 consecutive patients with severe pre-eclampsia remote from term
20. Temporising management of severe pre-eclampsia with and without the HELLP syndrome
21. The effect of acute volume expansion and vasodilatation with verapamil on uterine and umbilical artery Doppler indices in severe preeclampsia
22. Perinatal results of hemodynamic and conservative temporizing treatment in severe pre-eclampsia
23. Bed rest: a potentially harmful treatment needing more careful evaluation
24. Nifedipine in the treatment of severe preeclampsia
25. Daily antenatal testing in women with severe preeclampsia
26. Management of complicated preeclampsia
27. Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks' gestation: a randomized controlled trial
28. Aggressive versus expectant management of severe preeclampsia at 28-32 weeks' gestation: a randomized controlled trial
29. Risk factors for abruptio placentae and eclampsia: analysis of 445 consecutively managed women with severe preeclampsia and eclampsia
30. Maternal and perinatal outcome associated with hypertensive crises of pregnancy
31. Pre-eclampsia-eclampsia. Current problems in obstetrics
32. Maternal-perinatal outcome in 254 consecutive cases
33. Prevention of eclampsia
34. Persistence of cerebral hemodynamic changes in patients with eclampsia: A report of three cases
35. Magnesium for preeclampsia and eclampsia
36. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia
37. Cardiovascular alterations in severe pregnancy-induced hypertension: acute effects of intravenous magnesium sulfate
38. Circulatory effects of magnesium sulfate in normotensive and renal hypertensive pregnant sheep
39. Effects of magnesium sulfate on toxemic patients in labor
40. A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia
41. Magnesium: nature's physiologic calcium blocker
42. The case of magnesium sulphate in preeclampsia-eclampsia
43. Analysis of the risks associated with calcium channel blockade: implications for the obstetrician-gynecologist
44. Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia?
45. The use of nimodipine in a patient with eclampsia: color flow Doppler demonstration of retinal artery relaxation
46. Preeclampsia may cause both overperfusion and underperfusion of the brain: a cerebral perfusion based model
47. Management of eclampsia
48. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy
49. Erythrocyte morphology in women with severe preeclampsia and eclampsia. Preliminary observations with scanning electron microscopy
50. HELLP, Microangiopathic Hemolytic Anemia, and Preeclampsia
51. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much ado about nothing?
52. Maternal-perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia-eclampsia
53. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome)
54. Neonatal outcome in severe preeclampsia at 24 to 36 weeks' gestation: does the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter?
55. Clinical utility of strict diagnostic criteria for the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome
56. The natural history of HELLP syndrome: patterns of disease progression and regression
57. The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification
58. Maternal and perinatal outcome after expectant management of the HELLP syndrome compared with pre-eclampsia without HELLP syndrome
59. Plasma glutathione S-transferase alpha 1-1: a more sensitive marker for hepatocellular damage than serum alanine aminotransferase in hypertensive disorders of pregnancy
60. Plasma glutathione S-transferase Pi 1-1 measurements in the study of hemolysis in hypertensive disorders of pregnancy
61. Haptoglobin as a sensitive marker of hemolysis in HELLP-syndrome
62. 31P magnetic resonance spectroscopy of the liver in HELLP syndrome
63. HELLP! A cry for laboratory assistance: a comprehensive review of the HELLP syndrome highlighting the role of the laboratory
64. Preeclampsia: an excessive maternal inflammatory response to pregnancy
65. Corticosteroids for the enhancement of fetal lung maturity: impact on the gravida with preeclampsia and the HELLP syndrome
66. Postpartum corticosteroids: accelerated recovery from the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP)
67. Antepartum corticosteroids: disease stabilization in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP)
68. HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: the benefit of corticosteroids
69. Repeated antenatal corticosteroids: size at birth and subsequent development
70. Intravenous prostacyclin in the management of pregnancies complicated by severe hypertension
71. 2 serotonergic receptor antagonist, could be useful in the HELLP syndrome
72. Die Bedeutung der fruhzeitigen Diagnose und unverzuglichen Entbindung bei patientinnen mit HELLP-Syndrom
73. Early risk assessment of severe preeclampsia: admission battery of symptoms and laboratory tests to predict likelihood of subsequent significant maternal morbidity
74. Recommendations on blood pressure measurement
75. Comparison of auscultatory versus an oscillometric ambulatory blood pressure monitor in normotensive, hypertensive, and preeclamptic pregnancy
76. Lack of reproducibility in pregnancy of Korotkoff phase IV as measured by mercury sphygmomanometry
77. Randomised trial of management of hypertensive pregnancies by Korotkoff phase IV or phase V
78. Comparison of auscultatory and oscillometric automated blood pressure monitors in the setting of preeclampsia
79. The laboratory evaluation of hypertensive gravidas
80. Liver function tests in pre-eclampsia: importance of comparison with a reference range derived for normal pregnancy
81. The classification and definition of the hypertensive disorders of pregnancy
82. Urinary dipstick protein: a poor predictor of absent or severe proteinuria
83. Urinary protein/creatinine ratio in hypertensive pregnant women
84. The importance of urinary protein excretion during conservative management of severe preeclampsia
85. Prognosis for pre-eclampsia complicated by 5 g or more of proteinuria in 24 h
86. Cardiovascular alterations in severe pregnancy-induced hypertension: relationship of central venous pressure to pulmonary capillary wedge pressure
87. Pulmonary edema in severe preeclampsia-eclampsia: analysis of thirty-seven consecutive cases
88. Surveillance of the pregnant hypertensive patient with Doppler flow velocimetry
89. Antepartum assessment of fetal condition by means of cardiotocogarphy
90. Antenatal corticosteroid therapy and fetal behaviour: a randomised study of the effects of betamethasone and dexamethasone
91. Pregnancies complicated by idiopathic intrauterine growth retardation. Severity of growth failure, neonatal morbidity and two-year infant neurodevelopment outcome
92. Expectant management of severe preeclampsia remote from term